Wednesday July 24, 2024
3:00 PM –4:15 PM ET
Please note this live virtual meeting is at: 3:00 PM Eastern; 2:00 PM Central; 1:00 PM Mountain; 12:00 PM Pacific
PROGRAM FEATURES
- Downloadable whiteboard animations
- Interactive, case-based learning environment
- Create-your-own personalized poster
FACULTY
 |
Emily K. Sims M.D, M.S Associate Professor of Pediatrics Pediatric Endocrinology and Diabetology Center for Diabetes and Metabolic Diseases Indiana University School of Medicine Assistant Director of Faculty Development and Translational Research Herman B Wells Center for Pediatric Research Associate Director, IU Medical Scientist Training Program Indianapolis, Indiana |
 |
Richard Oram, MD, PhD Associate Professor Diabetes UK Harry Keen Fellow University of Exeter Medical School Exeter, UK |
PROGRAM OVERVIEW
During this program, experts will present overviews of the importance of early screening and staging for type 1 diabetes (T1D), strategies and practical pearls for screening and follow-up, how to intervene early with disease-modifying therapies to delay progression to clinical T1D, as well as ongoing therapeutic advances in this setting. The program will be highly interactive, with case-based discussions, Q & A, and engaging animations to facilitate the uptake of key concepts in early T1D, and to allow for increased interaction with the expert faculty.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Pediatric Endocrinologists, Adult Endocrinologists, Pediatricians, Primary Care Providers (PCPs), and Endocrine Nurses. Additionally, accessible programming and tools will be designed for patients, relatives, and members of the general population. As discussed within program descriptions, activities will be designed in a manner that allows learners to choose programming most relevant to their professional needs.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 CPEU
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
